Bayesian Trial Design for Clinical Trials

Why Use Bayesian Methods in Clinical Research?

Adaptive Design Flexibility

Adapt to new information as it emerges while maintaining statistical rigour.

Ethical Efficiency

Reduce patient exposure to ineffective treatments through early stopping rules.

Regulatory Recognition

Supported by the FDA and EMA, especially in rare diseases, oncology, and device trials.

Enhanced Stakeholder Communication

Probability-based outputs are more intuitive for sponsors, investigators, and regulators.

Using Bayesian Statistics to Support Rare Disease Research Innovations

Using Bayesian Statistics to Support Rare Disease Research Innovations

February 28th, 2025 1 minute read

On Rare Disease Day, we highlight the potential of Bayesian statistics to overcome recruitment challenges in rare dis…

Advancing Clinical Trial Design with Bayesian Statistics and Prior Elicitation

Advancing Clinical Trial Design with Bayesian Statistics and Prior Elicitation

April 1st, 2025 1 minute read

Discover how Bayesian statistics can enhance clinical trial efficiency and improve decision-making. Our latest white …

Webinar Report on Expert Prior Elicitation in Clinical Trials

Webinar Report on Expert Prior Elicitation in Clinical Trials

March 20th, 2025 4 minute read

Introduction   Our webinar explored the use of expert prior elicitation techniques in clinical research, pa…

Strengthening Causal Inference with Sensitivity Analyses: Using the Bayesian Parametric G-Formula

Strengthening Causal Inference with Sensitivity Analyses: Using the Bayesian Parametric G-Formula

February 19th, 2025 2 minute read

Understanding causal relationships in real-world data is challenging, particularly in observational studies, where co…

Bayesian Statistics: An Important Yet Underutilized Paradigm in Rare Disease and Small Population Drug Development

Bayesian Statistics: An Important Yet Underutilized Paradigm in Rare Disease and Small Population Drug Development

April 26th, 2024 1 minute read

Giles Partington, Principal Statistician at Phastar, recently provided an article for Clinical Research News explaini…

Benefits and Risks of the BOIN12 Design for Early Phase Oncology Trials under the Paradigm of Project Optimus

Benefits and Risks of the BOIN12 Design for Early Phase Oncology Trials under the Paradigm of Project Optimus

October 1st, 2024 9 minute read

Since the introduction of Project Optimus by the FDA in 2020 [1], it has become more important than ever to ensure th…

Bayesian Trial Design FAQs

+
A Bayesian trial uses probability and prior data to update beliefs about treatment effects as new evidence is collected. This approach supports more flexible and adaptive trial structures.
+
Traditional trials rely on fixed sample sizes and pre-specified analyses. Bayesian designs update continuously, allowing for interim reviews and faster decisions.
+
Yes. Prior data from earlier studies or expert input can be formally incorporated to improve efficiency and reduce required sample sizes.
+
Yes. Both the FDA and EMA support Bayesian designs, particularly in areas like medical devices, rare diseases, and adaptive studies.
+
-Rare disease trials or small patient populations
-Early-phase studies
-Adaptive or platform trials
-Trials with strong ethical considerations
+
Bayesian approaches often require specialized software and expertise, but they provide more informative results and flexible decision-making.
+
Yes. Bayesian trials can incorporate standard methodological controls like randomization and blinding, ensuring scientific rigor is maintained.

Let’s Talk About How Bayesian Approach Could Benefit Your Next Trial

Contact Phastar to learn more about our Bayesian Trial Design